<DOC>
	<DOCNO>NCT00458809</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin , work different way stop growth tumor cell , either kill cell stop dividing . Hyperthermia therapy kill tumor cell heat several degree normal body temperature . Adding chemotherapy hyperthermia infuse directly abdomen may kill tumor cell . Giving treatment surgery may kill tumor cell remain surgery . PURPOSE : This phase I trial study side effect best dose intraperitoneal hyperthermic perfusion oxaliplatin treat patient stage IV peritoneal cancer due appendix cancer colorectal cancer .</brief_summary>
	<brief_title>Intraperitoneal Hyperthermic Perfusion With Oxaliplatin Treating Patients With Stage IV Peritoneal Cancer Due Appendix Cancer Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity intraperitoneal hyperthermic chemoperfusion oxaliplatin patient stage IV peritoneal surface malignancy primary colorectal appendiceal cancer . - Determine pharmacokinetics drug perfusate , normal peritoneum , peritoneal surface tumor patient . - Evaluate expression protein involve apoptotic stress-inducible heat shock protein pathway ( e.g. , Fas , TRAIL , DISC component [ FADD , TRADD , FLIP , caspase 8 ] , mitochondrial protein [ Bax , Bak , Bcl-2 , Bcl-X_L ] , heat shock protein [ HSPs 27 , 40 , 70 90 ] ) drug therapy . OUTLINE : This nonrandomized , open-label , dose-escalation study . Patients undergo gross tumor resection day 1 . After tumor debulking , patient receive oxaliplatin 2 hour intraperitoneal hyperthermic chemotherapy ( IPHC ) . Cohorts 3-6 patient stratum receive escalating dos oxaliplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 6 patient treated MTD . Patients undergo blood tissue sample IPHC pharmacokinetic study evaluation protein involve apoptosis heat-shock-mediated cell death ( e.g. , Fas , TRAIL , FADD , TRADD , FLIP , caspase 8 , Bax , Bak , Bcl-X , heat shock proteins 27 , 40 , 70 , 90 ) . After completion study treatment , patient follow periodically least 1 year . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Appendiceal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm colorectal appendiceal cancer Stage IV disease Peritoneal surface dissemination disease ( peritoneal carcinomatosis ) Measurable disease accord RECIST criterion No active CNS metastases PATIENT CHARACTERISTICS : ECOG performance status 02 Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Creatinine ≤ 1.5 mg/dL OR creatinine clearance &gt; 60 mL/min Bilirubin ≤ 1.5 mg/dL Alkaline phosphatase ≤ 3 time upper limit normal ( ULN ) AST ALT ≤ 3 time ULN No active infection fever ≥ 101.3°F within past 3 day No malignancy within past 5 year except curatively treat basal cell skin cancer , cervical intraepithelial neoplasia , localized prostate cancer current prostatespecific antigen &lt; 1.0 mg/dL 2 successive evaluation , ≥ 3 month apart , last evaluation within past 4 week No peripheral neuropathy ≥ grade 2 No medical condition , mental illness , substance abuse , opinion principal investigator , would preclude study compliance No known hypersensitivity component oxaliplatin No know HIV positivity No hepatitis B C positivity ( active , previously treat , ) Not pregnant nursing Negative pregnancy test Fertile patient partner must use effective contraception 90 day completion study treatment PRIOR CONCURRENT THERAPY : Recovered prior surgery , radiotherapy , anticancer therapy More 30 day since prior concurrent investigational therapy No prior radiotherapy &gt; 25 % bone marrow No prior allogeneic stem cell transplantation No concurrent antiretroviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>carcinoma appendix</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>